Evolus Inc at Canaccord Genuity Growth Conference Transcript
Good morning, everyone, and thank you for attending our conference. I'm Susan Anderson, one of Canaccord's analysts in the consumer space. And we're very excited to have here, Evolus and in particular Sandra Beaver, the Company CEO -- sorry, CFO.
Sandra, perhaps you can maybe start off with a quick overview of Evolus and the importance of the brand and being a beauty brand and not necessarily a pharma brand and maybe also go for the products that you guys have.
Sure. Thanks, Susan, and thanks so much for having us. We're super excited to be here, first time at this conference. So I appreciate the opportunity to speak with you all.
So Evolus is a company that has a single product today. The product is a neurotoxin product named Jeuveau, outside of the US it's also called Nuceiva. Jeuveau is a neurotoxin that is on par with if not slightly better than the market leading neurotoxin, BOTOX, which I'm sure you're all familiar with. Jeuveau has been on the market
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |